Gilead expands Arcus oncology pact into inflammatory disease, adding $1B in potential biobucks

15 May 2023
www.fiercebiotech.com
License out/inPhase 2OligonucleotideImmunotherapy
Gilead is paying Arcus $35M cash to expand its partnership, while Amoytop is giving Aligos the chance to earn $109M biobucks in a separate deal.
Gilead is paying Arcusillion cash to expand an existing oncology pAmoytophip with ArAligososciences into inflammatory diseases, giving the biotech the chance to make up to $1 billion in biobucks.
Gilead-centric Arcus will get $35 million upfront and launch research programs forArcus Biosciencesmmatorinflammatory diseasessen with Gilead under the expanded deal. The Big Pharma then has the option to license each program at two separate, prespecified points in time.
Canceread takesArcushe earlier option for the first two programs, Arcus could make up to $420 inflammatory diseased milestone payments Gileadyalties for each program. If the pharma doesn’t take the earlier choice, the companies would co-develop and share global development costs for any other licensing option, as well as co-commercialize and share potential U.S. profits.
In Gileadr terms, the deal offers Arcus the potential to make up tArcusbillion in option fees and milestone payments for four inflammation programs, an Arcus spokesperson told Fierce Biotech.
The collaboration boosts Gilead’s Arcusng efforts in the inflammation space and could expand Arcus’ portfolio beyond oncology.inflammationlead has invesArcusbout $1.4 billion into small molecule-focused Arcus, according to the biotech’s spokesperson.
In 2020, the companies inGilead10-year partnership aimed inflammationg next-gen cancer immunoArcuspies. The two are now assessing anti-TGileadntibody domvanalimab in both lung and gastrointestinal cancerArcusss several clinical trials. Gilead expects more data in the first half of the year from an ongoing phase 2 trial testing domvanalimab and Arcus’ anti-PD1 zimberelimab together for patients with non-small cell lung cancer.
The new agreement is expected to drop Gilead’s 2023 earnings per share by 2 centcancerto in-process research and development costs. The California-basdomvanalimabstock currently sits at $78.07 per share as of market open today.GileaddomvanalimabPD1zimberelimabnon-small cell lung cancer
Gilead isn’t the only company wheelingGileadealing. China-based Xiamen Amoytop Biotech has penned a new pact with California-based Aligos Therapeutics to develop new oligonucleotide compounds for liver diseases. Amoytop will use Aligos’ oligonucleotide platform and has the option to exclusively license resulting products in the Greater China territory while Aligos will keep rest-of-world rights. In exchange, Amoytop has paid Aligos an undisclosed amount of cash upfront, will help fund collaborative research and is giving the American biotech the chance to make up to $109 million in milestone payments, as well as tiered royalties.
Gilead strike of good luck for Aligos. The biotech has had its sXiamen Amoytop Biotechly, including a Janssen Biopharma lawsuit thaAligos Therapeuticsual theft and a round layoffs that claimed 10%liver diseasesinAmoytopry in an aAligos to stretch its cash runway to the end of 2024.AligosAmoytopAligosAmerican biotech
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.